2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-136459
    NMDA receptor antagonist 2 875898-41-2
    NMDA receptor antagonist 2 is a potent and orally active NR2B subtype-selective NMDA antagonist with an IC50 and a Ki of 1.0 nM and 0.88 nM, respectively. NMDA receptor antagonist 2 is used for the study of neuropathic pain and Parkinson’s disease.
    NMDA receptor antagonist 2
  • HY-14200A
    (S)-Rasagiline mesylate 202464-88-8
    (S)-Rasagiline (TVP1022) mesylate is the relatively inactive S-enantiomer form of Rasagiline mesylate. Rasagiline mesylate is a highly potent selective irreversible MAO inhibitor with IC50s of 4.43 nM and 412 nM for rat brain MAO B and A activity, respectively.
    (S)-Rasagiline mesylate
  • HY-142661
    BAY 1217224 1639886-32-0
    BAY 1217224 is a neutral, non-proagent Thrombin inhibitor with good oral pharmacokinetics.
    BAY 1217224
  • HY-145353
    HTL22562 2097085-63-5
    HTL22562 is a calcitonin gene-related peptide (CGRP) receptor antagonist for acute research of migraine.
    HTL22562
  • HY-146678
    HDAC6-IN-5 2413603-15-1
    HDAC6-IN-5 (compound 11b) is a potent and BBB-penetrated HDAC6 inhibitor, with an IC50 of 0.025 μM. HDAC6-IN-5 exhibits strong inhibitory activity against Aβ1-42 self-aggregation and AChE, with IC50 values of 3.0 and 0.72 μM. HDAC6-IN-5 can enhance neurite outgrowth without significant neurotoxicity.
    HDAC6-IN-5
  • HY-14946S
    Amifampridine-d3 2732980-95-7
    Amifampridine-d3 (3,4-Diaminopyridine-d3) is deuterium labeled Amifampridine. Amifampridine (3,4-Diaminopyridine) is an orally active, potent and cell permeable voltage-gated potassium (Kv) channel blocker (PCB). Amifampridine is efficacy in the reversal of BoNT/A (HY-P79153) intoxication. Amifampridine increases transmitter release from neuromuscular junctions (NMJs). Amifampridine can be used for Lambert-Eaton myasthenic syndrome (LEMS) research.
    Amifampridine-d3
  • HY-151615
    DCI-Br-3
    DCI-Br-3 is a rapid, highly sensitive, and selective probe to monitor thiols in the epileptic brain. (λex=537 nm, λem=675 nm).DCI-Br-3 can effectively cross the blood-brain barrier (BBB).
    DCI-Br-3
  • HY-155188
    NWP-0476 2290611-26-4
    NWP-0476 is BCL-2/BCL-xL inhibitor. NWP-0476 has a modified structure with fine-tuned BCL-xL activity. NWP-0476 can be used for relapsed T-acute lymphoblastic leukemia (T-ALL) research.
    NWP-0476
  • HY-155238
    E2730 1520073-91-9
    E2730 is a noncompetitive but selective inhibitor of gamma-aminobutyric acid (GABA) transporter 1 (GAT1) with orally available and antiepileptic activity. E2730-mediated GAT1 inhibition is positively correlated with environmental GABA levels and selectively inhibits GAT1-mediated GABA uptake. E2730 (5-50 mg/kg; po) in rat amygdala ignition model, and in mouse cornea ignition (5-50 mg/kg), drug resistance 6Hz-44mA has demonstrated in vivo efficacy in models of psychomotor epilepsy (5-50 mg/kg), fragile X syndrome (2.5-300 mg/kg), and Dravet syndrome (10 mg/kg, 20 mg/kg).
    E2730
  • HY-155349
    AChE/BuChE-IN-4 1997158-25-4 99.66%
    AChE/BuChE-IN-4(compound 4a) is aorally activeandbrain-penetrantmultitarget-directedAChE/BuChEinhibitor againstAChEandBuChE, with theIC50of 2.08 and 7.41 μM.
    AChE/BuChE-IN-4
  • HY-159504
    Pregabalinum naproxencarbilum 1221072-91-8
    Pregabalinum naproxencarbilum (Pregabalin naproxencarbil) is a gabamimetic (GABA), analgesic compound.
    Pregabalinum naproxencarbilum
  • HY-159524
    Matsupexolum 1399442-97-7
    Matsupexolum (Matsupexole) is a dopamine receptor agonist.
    Matsupexolum
  • HY-159527
    Glovadalenum 2576359-31-2
    Glovadalenum (Glovadalen) is a dopamine D1 receptor positive allosteric modulator.
    Glovadalenum
  • HY-163174
    II399 2928480-72-0
    II399 is a potent, selective NNMT bisubstrate inhibitor containing an unconventional SAM mimic, with a Ki of 5.9 nM. II399 exhibits an explicit pattern of competitive inhibition for NAM. II399 occupies both the substrate and cofactor binding pockets. II399 has the potential for the research of cancers, metabolic, cardiovascular, and neurodegenerative diseases.
    II399
  • HY-168537
    LB-102 2227154-23-4
    LB-102 is an orally active inhibitor of dopamine D2, D3, and 5-HT7 receptors, which can be used in research on schizophrenia and other psychiatric disorders.
    LB-102
  • HY-169964
    TSPO/Carbonic Anhydrase Modulator 1
    TSPO/Carbonic Anhydrase Modulator 1 (Compound 3) is a dual modulator for mitochondrial translocator protein and Carbonic Anhydrase with a Ki of 1.340 μM for TSPO and a KA of 10.7 μM for CA VII. TSPO/Carbonic Anhydrase Modulator 1 promotes the production of neurosteroid, increases BDNF gene expression, exhibits neuroprotective efficacy.
    TSPO/Carbonic Anhydrase Modulator 1
  • HY-172236
    Soclenicant 1020634-41-6 99.75%
    Soclenicant (BNC210) is an orally active α7 nAChR negative alteration modulator (NAM) with no apparent side effects. Soclenicant exhibits acute anxiolytic activity in rodent models of anxiety. Soclenicant inhibits rat and human α7 nAChR currents (in stably transfected cell lines) induced by acetylcholine, nicotine, choline, and the a7-specific agonist PNU-282987 (HY-12560A) with IC50 values in the range of 1.2 to 3 μM. Soclenicant can be used in studies of anxiety, trauma, and stressor-related disorders.
    Soclenicant
  • HY-172318
    IAMA-6 2497525-96-7
    IAMA-6 is a selective NKCC1 inhibitor with neuroprotective effects. IAMA-6 can be used for the study of brain conditions, including drug-resistant epilepsy (e.g. temporal lobe epilepsy (TLE) and Dravet syndrome (DrS)), autism spectrum disorders (ASD) and Down syndrome (DoS).
    IAMA-6
  • HY-34740R
    Ethylmalonic acid (Standard) 601-75-2
    Ethylmalonic acid (Standard) is the analytical standard of Ethylmalonic acid. This product is intended for research and analytical applications. Ethylmalonic acid is non-carcinogenic potentially toxic and associated with anorexia nervosa and malonyl-CoA decarboxylase deficiency.
    Ethylmalonic acid (Standard)
  • HY-B1331R
    Cyromazine (Standard) 66215-27-8
    Cyromazine (Standard) is the analytical standard of Cyromazine. This product is intended for research and analytical applications. Cyromazine (CGA-72662) is a triazine insect growth regulator used as an insecticide and an acaricide. It is a cyclopropyl derivative of melamine. Cyromazine works by affecting the nervous system of the immature larval stages of certain insects. Cyromazine reduced the number of germ cells by interfering with the Ecdysone (HY-N0179) signaling pathway. Cyromazine induces renal toxicity attenuated and restored by green tea extract in rats.
    Cyromazine (Standard)
Cat. No. Product Name / Synonyms Application Reactivity